Profitability:
The parent’s Q4 2025 materials attribute roughly $11 million of adjusted EBITDA and $31 million of revenue in that quarter to Iodine’s post‑close contribution, indicating immediate earnings impact. The completed $1.25 billion transaction and quantifiable P&L effects signal profit‑generating scale inside the combined company.
Market Expansion:
Waystar reported growth in large clients in Q4 2025, with about half of that quarter’s increase coming from Iodine’s customer base, enlarging the combined footprint. Guidance and deal rationale reference an expanded addressable market and continued growth from the integrated business.
Product Line Growth:
Iodine launched a next‑generation pre‑bill optimization product in May 2025 and broadened commercial leadership, signaling ongoing investment in new offerings. Its scope extends beyond core CDI into utilization management, pre‑bill integrity, and denials/appeals, reflecting continued portfolio expansion.
